Artemether-lumefantrine: An option for malaria;Artemether-lumefantrina: Una Opción para la Malaria

Annals of Pharmacotherapy

Volumn 46, Issue 4, 2012, Pages 567-577

  Stover, Kayla R ^a   Travis King, S ^b   Robinson, Jessica ^c  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c Robert C Byrd Center for Pharmacy Education   (United States)

Author keywords

Artemether lumefantrine; Coartem; Malaria; Plasmodium falciparum

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; CONTRACEPTIVE AGENT; DAPSONE; DIHYDROARTEMISININ; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; MEFLOQUINE; PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; ASTHENIA; CENTRAL NERVOUS SYSTEM DISEASE; COMPARATIVE STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG COST; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA FALCIPARUM; MYALGIA; NAUSEA; NONHUMAN; PARASITE CLEARANCE; PATIENT COMPLIANCE; PATIENT EDUCATION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TABLET; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHANOLAMINES; FLUORENES; HUMANS; MALARIA, FALCIPARUM; MEDICATION ADHERENCE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION;

EID: 84859713175     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q539     Document Type: Article

References (68)

1. Malaria. Centers for Disease Control and Prevention. www.cdc.gov/malaria (accessed 2011 Aug 9).
2. Product information. Coartem (artemether and lumefantrine). East Hanover, NJ: Novartis Pharmaceuticals Corp., February 2010.
3. White NH, Breman JG. Malaria. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill, 2008:1280-94.
4. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization, 2010.
5. Premji ZG. Coartem: the journey to the clinic. Malar J 2009;8(suppl 1):S3.
6. Hassan Alin M, Bjorkman A, Wernsdorfer WH. Synergism of beflumetol and artemether in Plasmodium falciparum. Am J Trop Med Hyg 1999;61:439-45.
7. Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE. Current perspectives on the mechanism of action of artemisinins. Int J Parasitol 2006;36:1427-41.
8. Kokwaro G, Mwai L, Nzila A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother 2007;8:75-94.
9. Djimde A, Lefevre G. Understanding the pharmacokinetics of Coartem. Malar J 2009;8(suppl 1):S4.
10. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999;37: 105-25.
11. Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol 1998;46:553-62.
12. Ashley EA, Stepniewska K, Lindegardh N, et al. How much fat is necessary to optimize lumefantrine oral bioavailability. Trop Med Int Health 2007;12:195-200.
13. Premji ZG, Abdulla S, Ogutu B, et al. The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence. Malar J 2008;7:244.
14. Product information. Coartem dispersible (artemether and lumefantrine). Basel, Switzerland: Novartis Pharma AG, May 2009.
15. Djimde AA, Tekete M, Abdulla A, et al. Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemetherlumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2011;55:3994-9.
16. Price RN, Uhlemann AC, van Vugt, et al. Molecular and pharmacologic determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006;42:1570-7.
17. Ezzet F, van Vugt M, Nosten F, et al. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000;44:697-704.
18. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997;41:1413-22.
19. White NJ. Preventing antimalarial drug resistance through combinations. Drug Resistance Updates 1998:1:3-9.
20. Lefevre G, Marrast AC, Grueninger H. Novartis malaria initiative: best practice example of pharmaceutical industry's engagement in the fight against malaria. Ann NY Acad Sci 2011;1222:19-29.
21. Makanga M, Krudsood S. The clinical efficacy of artemether/lumefantrine (Coartem). Malar J 2009;8(suppl 1):S5.
22. Achan J, Tibenderana JK, Kyabayinze D, et al. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children randomized trial. BMJ 2009;339:b2763.
23. Arinaitwe E, Sandison TG, Wanzira H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 2009;49:1629-37.
24. Bassat Q, Mulenga M, Tinto H, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomized, non-inferiority trial. PLoS One 2009;4: e7871.
25. Bell DJ, Wootton D, Mukaka M, et al. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar J 2009;8:204.
26. Faucher JF, Aubouy A, Adeothy A, et al. Comparison of sulfadoxinepyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated Plasmodium falciparum malaria in Benin: a randomized effectiveness trial. J Infect Dis 2009;200:57-65.
27. Premji Z, Umeh RE, Owusu-Agyei S, et al. Chlorproguanil-dapsoneartesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. PLoS One 2009;4:e6682.
28. Sagara I, Rulisa S, Mbacham W, et al. Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemetherlumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-center trial. Malar J 2009;9:63.
29. Toure OA, Penali LK, Yapi JD, et al. A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/ lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Cote d'Ivoire. Malar J 2009;8:148.
30. Valecha N, Srivastava P, Mohanty SS, et al. Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India. Malar J 2009;8:107.
31. Adam I, Salah MT, Eltahir HG, Elhassan AH, Elmardi KA, Malik EM. Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan. Ann Trop Med Parasitol 2010;104:319-26.
32. Elamin SB, Awad AI, Eltayeb IB, et al. Descriptive study on the efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Sudan. Eur J Clin Pharmacol 2010;66:231-7.
33. Faye B, Offianan AT, Ndiaye JL, et al. Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop Med Int Health 2010;15:608-13.
34. Faye B, Ndiaye AJ, Tine R, et al. A randomized trial of artesunate mefloquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. Am J Trop Med Hyg 2010;82:140-4.
35. Michael OB, Gbotosho GO, Folarin OA, et al. Early variations in Plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance. Malar J 2010;9:335.
36. Okafor HU, Shu EN, Oguonu T. Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance. J Trop Pediatr 2010;56:398-406.
37. Piola P, Nabasumba C, Turyakira E, et al. Efficacy and safety of artemetherlumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomized, noninferiority trial. Lancet Infect Dis 2010;10:762-9.
38. Schoepflin S, Lin E, Kiniboro B, et al. Treatment with coartem (artemetherlumefantrine) in Papua New Guinea. Am J Trop Med Hyg 2010;82:529-34.
39. Gbotosho GO, Sowunmi A, Okuboyejo TM, et al. Therapeutic efficacy and effects of artemether-lumefantrine and artesunate-amodiaquine coformulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in southwest Nigeria. Am J Trop Med Hyg 2011;84:813-9.
40. Nambozi M, Van Geertruyden JP, Hachizovu S, et al. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J 2011;10:50.
41. Ngasala BE, Malmberg M, Carlsson AM, et al. Effectiveness of artemetherlumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study. Malar J 2011;10:64.
42. Ngasala BE, Malmberg M, Carlsson AM, et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falci-parum malaria in rural Tanzania: a randomized trial. Clin Infect Dis 2011;52:873-82.
43. Toure OA, Kouame MG, Didier YJ, et al. Artesunate/mefloquine paediatric formulation vs artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum in Anonkoua koute, Cote d'Ivoire. Trop Med Int Health 2011;16:290-7.
44. Ursing J, Kofoed PE, Rodrigues A, et al. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis 2011;203:109-16.
45. Mueller EA, van Vugt M, Kirch W, Andriano K, Hunt P, Ibarra de Palacios P. Efficacy and safety of the six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: a pooled analysis of individual patient data from randomized clinical trials. Acta Tropica 2006;100:41-53.
46. Makanga M, Premji Z, Falade C, et al. Efficacy and safety of the sixdose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg 2006;74:991-8.
47. Woodring JV, Ogutu B, Schnabel D, et al. Evaluation of recurrent parasitemia after artemether-lumefantrine treatment for uncomplicated malaria in children in western Kenya. Am J Trop Med Hyg 2010;83:458-64.
48. Whegang SY, Tahar R, Foumane VN, et al. Efficacy of non-artemisininand artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon. Malar J 2010;9:56.
49. Falade C, Manyando C. Safety profile of Coartem: the evidence base. Malar J 2009;8(suppl 1):S6.
50. Katrak S, Gasasira A, Arinaitwe E, et al. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Malar J 2009;8:272.
51. Maiteki-Sebuguzi C, Jagannathan P, Yau VM, et al. Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar J 2008;7:106.
52. Bindschedler M, Lefevre G, Degen P, Sioufi A. Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in health participants. A J Trop Med Hyg 2002;66:293-8.
53. German P, Parikh S, Lawrence J, et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 2009;51:424-9.
54. Abdulla A, Sagara I, Borrmann S, et al. Efficacy and safety of artemetherlumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 2008;372:1819-27.
55. Newman RD, Parise ME, Slutsker L, et al. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop Med Int Health 2003;8:488-506.
56. El-Dakdoky MH. Evaluation of the developmental toxicity of artemether during different phases of rat pregnancy. Food Chem Toxicol 2009;47: 1437-41.
57. Manyando C, Mkandawire R, Puma L, et al. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar J 2010;9:249.
58. McGready R, Tan SO, Ashley EA, et al. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med 2008;5:e253.
59. Kabanywanyi AM, Lengeler C, Kasim P, et al. Adherence to and acceptability of artemether-lumefantrine as first-line antimalarial treatment: evidence from a rural community in Tanzania. Malar J 2010;9:48.
60. Mizuno Y, Kato Y, Kudo K, Kano S. First case of treatment failure of artemether-lumefantrine in a Japanese traveler with imported falciparum malaria. Jpn J Infect Dis 2009;62:139-41.
61. Some AF, Sere YY, Dokomajilar C, et al. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother 2010;54:1949-54.
62. Happi CT, Gbotosho GO, Folarin OA, et al. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother 2009;53: 888-95.
63. Wiseman V, Kim M, Mutabingwa TK, et al. Cost-effectiveness study of three antimalarial drug combinations in Tanzania. PLoS Med 2006;3: e373.
64. Chanda P, Masiya F, Chitah BM, et al. A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia. Malar J 2007;6:21.
65. Davis WA, Clarke PM, Siba PM, et al. Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bull World Health Organ 2011;89:211-20.
66. Red book online. Thomson Reuters, 2011. www.redbook.com (accessed 2011 Nov 23).
67. Guidelines for treatment of malaria in the United States. Atlanta, GA: Centers for Disease Control and Prevention. Updated 2011 Sept 23. www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf (accessed 2011 Nov 23).
68. Ezzet F, van Vugt, Nosten F, et al. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000;44:697-704.